Viridian Therapeutics has completed enrollment in the REVEAL-1 and REVEAL-2 clinical trials for VRDN-003. The trials appear to be related to the treatment of thyroid eye disease, with some outlets specifying that they are phase III trials. It is unclear what the current status or results of these trials are, as some outlets also mention separate trials with positive topline results, but it is not specified if these results are related to the REVEAL trials.